Biovectra Names Klosk, Mccauley to Board
21 October 2021 - - Canadian biotech and pharmaceutical CDMO Biovectra has appointed Gordon C. McCauley, president and CEO of adMare BioInnovations and Steven Klosk CEO (retired) Cambrex Corp., to its board of directors, the company said.

Gordon McCauley BA, MBA, ICD.D is an accomplished life science executive and investor, having served as president and senior executive of several health care enterprises.

As president and CEO of adMare, McCauley leads its mission to build companies, ecosystems, and talent in the life sciences industry.

adMare has over 25 portfolio companies that have attracted more than USD 1.4bn of investment with a combined value of over USD 3bn.

Steven Klosk BS, JD is a consummate executive of the life sciences industry with over 25 years of experience of CDMO leadership.

Klosk retired as CEO of Cambrex Corp. in 2020 after leading its sale to Permira, a global private equity firm.

During his tenure Cambrex became a leading global and fully integrated supplier of drug substances, drug product and testing services across the entire drug life cycle to both the innovator and generic pharmaceutical markets.

The company grew to over 2,000 employees spanning a network of 12 manufacturing and research and development sites in North America and Europe.

Biovectra is a global biotech and pharmaceutical CDMO (contract development and manufacturing organization) that specializes in clinical-to-commercial scale production capabilities for: biologics, bioreagents, fermented small molecules, synthetic small molecules, and active pharmaceutical ingredients.

Flexibility, creativity, process optimization and compliance are at the heart of our method.

With over 550 employees and cGMP facilities in Prince Edward Island and Nova Scotia, Canada we assure our programs advance on time and with the highest quality outcomes.